UM-164

• CAT Number: I014750
• CAS Number: 903564-48-7
• Molecular Formula: C30H31F3N8O3S
• Molecular Weight: 640.6862
• Purity: ≥95%
• Target: c-Src/p38 inhibitor
• Solubility: Soluble in DMSO
• InChI: InChI=1S/C30H31F3N8O3S/c1-18-6-7-22(37-27(43)20-4-3-5-21(14-20)30(31,32)33)15-23(18)38-28(44)24-17-34-29(45-24)39-25-16-26(36-19(2)35-25)41-10-8-40(9-11-41)12-13-42/h3-7,14-17,42H,8-13H2,1-2H3,(H,37,43)(H,38,44)(H,34,35,36,39)
• InChIKey: ANEBQUSWQAQFQB-UHFFFAOYSA-N
• SMILES: O=C(C1=CN=C(NC2=NC(C)=NC(N3CCN(CCO)CC3)=C2)S1)NC4=CC(NC(C5=CC=CC(C(F)(F)F)=C5)=O)=CC=C4C

UM-164 (Cat.No:I014750) is a chemical compound that functions as an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is an enzyme involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in cellular metabolism. UM-164 has shown promise in preclinical studies for its potential as an anticancer agent.

Reference

1: Ndagi U, Mhlongo NN, Soliman ME. Emergence of a Promising Lead Compound in the Treatment of Triple Negative Breast Cancer: An Insight into Conformational Features and Ligand Binding Landscape of c-Src Protein with UM-164. Appl Biochem Biotechnol. 2017 Dec 27. doi: 10.1007/s12010-017-2677-z. [Epub ahead of print] PubMed PMID: 29282631.2: Ndagi U, Mhlongo NN, Soliman ME. The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design. Mol Biosyst. 2017 May 30;13(6):1157-1171. doi: 10.1039/c6mb00848h. PubMed PMID: 28463369.3: Gilani RA, Phadke S, Bao LW, Lachacz EJ, Dziubinski ML, Brandvold KR, Steffey ME, Kwarcinski FE, Graveel CR, Kidwell KM, Merajver SD, Soellner MB. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer. Clin Cancer Res. 2016 Oct 15;22(20):5087-5096. Epub 2016 May 6. PubMed PMID: 27154914.